4.8 Review

Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review

期刊

FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.744774

关键词

inactivated influenza vaccine (IIV); safety; immunogenicity; vaccine efficacy; vaccine effectiveness (VE); young children; pregnant women

资金

  1. Research Council of Norway GLOBVAC program [284930]
  2. Ministry of Health and Care Services
  3. University of Bergen, Norway
  4. Trond Mohn Stiftelse [TMS2020TMT05]
  5. Helse Vest [F-11628]
  6. European Union [EU IMI115672, H2020 874866 INCENTIVE, H2020 101037867 VACCELERATE]
  7. Nanomedicines Flunanoair (ERA-NETet EuroNanoMed2 i JTC2016)

向作者/读者索取更多资源

Research shows that inactivated influenza vaccines (IIVs) are generally well tolerated in pregnant women and young children, generating good antibody responses and providing moderate to high protection rates against different influenza types. The efficacy/effectiveness of IIVs is around 50%-70% in pregnant women and 20%-90% in young children against lab-confirmed influenza, but depends on various factors.
Annual influenza vaccination is often recommended for pregnant women and young children to reduce the risk of severe influenza. However, most studies investigating the safety, immunogenicity, and efficacy or effectiveness of influenza vaccines are conducted in healthy adults. In this evidence-based clinical review, we provide an update on the safety profile, immunogenicity, and efficacy/effectiveness of inactivated influenza vaccines (IIVs) in healthy pregnant women and children <5 years old. Six electronic databases were searched until May 27, 2021. We identified 3,731 articles, of which 93 met the eligibility criteria and were included. The IIVs were generally well tolerated in pregnant women and young children, with low frequencies of adverse events following IIV administration; however, continuous vaccine safety monitoring systems are necessary to detect rare adverse events. IIVs generated good antibody responses, and the seroprotection rates after IIVs were moderate to high in pregnant women (range = 65%-96%) and young children (range = 50%-100%), varying between the different influenza types/subtypes and seasons. Studies show vaccine efficacy/effectiveness values of 50%-70% in pregnant women and 20%-90% in young children against lab-confirmed influenza, although the efficacy/effectiveness depended on the study design, host factors, vaccine type, manufacturing practices, and the antigenic match/mismatch between the influenza vaccine strains and the circulating strains. Current evidence suggests that the benefits of IIVs far outweigh the potential risks and that IIVs should be recommended for pregnant women and young children.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据